JNJ - Johnson & Johnson

NYSE - Nasdaq Real Time Price. Currency in USD
121.419
+0.069 (+0.06%)
As of 3:21PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close121.350
Open121.560
Bid121.260 x 1200
Ask121.270 x 900
Day's Range121.130 - 122.795
52 Week Range121.130 - 148.320
Volume3,315,566
Avg. Volume6,763,107
Market Cap325.664B
Beta0.59
PE Ratio (TTM)256.16
EPS (TTM)0.474
Earnings DateJul 17, 2018
Forward Dividend & Yield3.36 (2.57%)
Ex-Dividend Date2018-02-26
1y Target Est145.10
Trade prices are not sourced from all markets
  • InvestorPlace3 hours ago

    A Focus on Eye Care Is Setting Up Johnson & Johnson Stock for the Future

    While steady growth is appreciated by some investors, that’s not that great overall and doesn’t necessarily support its constant valuation premium. To that end, Johnson & Johnson needs to find some serious growth to keep investors coming back to its shares. Vision care is quickly becoming a major growth engine for JNJ.

  • 7 Dow Titans Rolling Over
    InvestorPlace5 hours ago

    7 Dow Titans Rolling Over

    U.S. equities were rolling over on Thursday as hopes for a quick resolution to U.S. trade discussions with China and its NATFA partners have faded amid fresh Twitter tirades from President Donald Trump that negotiations weren’t going the way he wants. Here are seven Dow Jones Industrial Average components under pressure. The company will next report results on July 27 before the bell.

  • Dow 30 Stock Roundup: GE's Transportation Unit to Merge With Wabtec, J&J & Glaxo's HIV Drug Gets EU Approval
    Zacks5 hours ago

    Dow 30 Stock Roundup: GE's Transportation Unit to Merge With Wabtec, J&J & Glaxo's HIV Drug Gets EU Approval

    The Dow endured another volatile week marked by key geopolitical developments.

  • AbbVie's Imbruvica's Phase III Study Meets Primary Endpoint
    Zacks6 hours ago

    AbbVie's Imbruvica's Phase III Study Meets Primary Endpoint

    AbbVie's (ABBV) phase III iLLUMINA study evaluating Imbruvica in combination with Gazyva meets its primary endpoint of improvement in progression-free survival.

  • 3 Likely Reasons Geron Stock Is Sizzling Hot Right Now
    Motley Fool7 hours ago

    3 Likely Reasons Geron Stock Is Sizzling Hot Right Now

    This biotech stock is skyrocketing. Here's why -- maybe.

  • What Is Geron Corporation's Downside Risk?
    Motley Fool8 hours ago

    What Is Geron Corporation's Downside Risk?

    Management's bold moves have been steadily stemming concerns about the company's future.

  • J&J Jury Asks Judge to Slap Cancer Warning on Baby Powder
    Bloomberg10 hours ago

    J&J Jury Asks Judge to Slap Cancer Warning on Baby Powder

    If Johnson & Johnson won’t put a warning on its baby powder that it may be tainted with asbestos, some jurors were ready to do it for them. A California jury weighing J&J’s punishment over its handling of its iconic baby powder asked a judge May 24 if they could force the company to warn consumers that its Johnson’s Baby Powder could be contaminated with asbestos, according to the law firm that won the case against the health-care giant. After the judge said no, the jury awarded $4 million in punitive damages Thursday to Joanne Anderson, a 68-year-old woman who claimed her deadly cancer was caused by asbestos in J&J’s baby powder.

  • Jury recommends $25M in Johnson & Johnson lawsuit
    Associated Press21 hours ago

    Jury recommends $25M in Johnson & Johnson lawsuit

    LOS ANGELES (AP) — A California jury delivered a $25.7 million verdict against Johnson & Johnson in a lawsuit brought by a woman who claimed she developed cancer by using the company's talc-based baby powder.

  • 5 Top Stock Trades for Friday Morning
    InvestorPlaceyesterday

    5 Top Stock Trades for Friday Morning

    President Trump decided to pull out of his meeting with North Korean leader Kim Jong Un and that’s left stocks under pressure. Here’s our top stock trades as a result. Top Stock Trades for Tomorrow #1: Advanced Micro (AMD)

  • Reutersyesterday

    J&J must pay $4 million in punitive damages in latest asbestos cancer trial

    The decision in Los Angeles Superior Court comes on top of $21.7 million in compensatory damages that the same jury awarded to the woman and her husband on Wednesday. Joanne Anderson, 68, was diagnosed with mesothelioma, a form of cancer closely linked to asbestos exposure.

  • J&J must pay $4 million in punitive damages in latest asbestos cancer trial
    Reutersyesterday

    J&J must pay $4 million in punitive damages in latest asbestos cancer trial

    The decision in Los Angeles Superior Court comes on top of $21.7 million in compensatory damages that the same jury awarded to the woman and her husband on Wednesday. Joanne Anderson, 68, was diagnosed with mesothelioma, a form of cancer closely linked to asbestos exposure.

  • PR Newswireyesterday

    California Jury Delivers $25.75 Million Verdict in Asbestos Case Tying Johnson's Baby Powder to Mesothelioma

    WEST COVINA, Calif., May 24, 2018 /PRNewswire/ -- A jury in California delivered a $25.75 million verdict against the maker of Johnson's Baby Powder for the deadly asbestos-caused cancer a woman developed after years of using the product. In addition, one juror asked the court whether it could require Johnson's Baby Powder to carry a warning in the future. The verdict by jurors in Los Angeles Superior Court before Judge Gloria White-Brown includes $21.75 million in compensatory damages and $4 million in punitive damages.

  • Benzingayesterday

    An ETF Play For Quality Stocks At A Fair Price

    Items viewed as high quality usually sport higher price tags than their lower quality counterparts. The same is true in financial markets. While it is widely expected that growth, momentum and — sometimes ...

  • J&J Verdict Reaches Almost $26 Million in Baby Powder Trial
    Bloombergyesterday

    J&J Verdict Reaches Almost $26 Million in Baby Powder Trial

    Johnson & Johnson was ordered by a California jury to pay $4 million in punitive damages to a 68-year-old woman who claimed her deadly cancer was caused by asbestos in the company’s baby powder. J&J said it would appeal. “We will continue to defend the safety of our product because it does not contain asbestos or cause mesothelioma,’’ said spokeswoman Carol Goodrich.

  • InvestorPlaceyesterday

    3 Pros, 3 Cons to Buying Medtronic PLC Stock

    Can Medtronic PLC (NYSE:MDT) get its stock back in rhythm? Up until mid-2015, Medtronic stock was a star performer. It doubled from 2013 up to that point. Since then, Medtronic has seriously underperformed. MDT stock has spent the last three years in a tight trading range between $70 and $90 per share, while the rest of the market has launched further upward.

  • InvestorPlaceyesterday

    3 Top Biosimilars that Will Lift Pfizer Inc. Stock Even More

    A month ago, Pfizer Inc. (NYSE:PFE) felt the sting of a somewhat surprising disappointment. Its biosimilar version of Herceptin, the popular breast cancer drug from Roche Holding AG (OTCMKTS:RHHBY), was rejected by the FDA.Biosimilar drugs are nearly-identical copies of a competitor’s product. It was a blow not just because Herceptin generated sales of more than $7 billion last year, but because it put the viability of Pfizer’s entire biosimilar program into question.

  • Barrons.comyesterday

    Biopharma M&A: You Ain't Seen Nothing Yet

    Barron's has previously discussed how mergers and acquisitions will be a theme for pharma and biotech. With Takeda Pharmaceutical’s (4502.Japan) deal to buy Shire (SHPG), Leerink's Geoffrey Porges takes a look at what other deals could come to fruition. If companies chose to borrow to make acquisitions, that wouldn't be a problem either, he argues, as the group could collectively borrow another $460 billion if the industry returned to its peak leverage ratios, and the biggest companies could easily absorb any acquisitions with little debt worries, especially with synergies.

  • 3 Big Pharma Stocks with Huge Future Growth Potential
    InvestorPlaceyesterday

    3 Big Pharma Stocks with Huge Future Growth Potential

    You might not be aware of it, but big pharma stocks have gone through a difficult period for many years. A lot of the big drugs at the big pharma stocks went off patent, and the revenue for some of the big pharma stocks has fallen off as a result. Some of the big pharma stocks were able to replace that revenue and some weren’t.

  • CNBCyesterday

    Stocks making the biggest moves premarket: BBY, MDT, HRL, MCK, DEO, FOXA, F, GM & more

    The electronics retailer earned an adjusted 82 cents per share for the first quarter , 8 cents a share above estimates, with revenue also exceeding forecasts. Best Buy reported a comparable store sales increase of 7.1 percent, well above the consensus Thomson Reuters forecast of a 3.0 percent increase. Medtronic MDT – The medical device maker's quarterly numbers came in 3 cents above estimates at an adjusted $1.42 per share, with revenue also above Street forecasts.

  • ACCESSWIREyesterday

    Ex-Dividend Alert: Johnson & Johnson Boosted its Dividend by 7.1%; Will Trade Ex-Dividend on May 25, 2018

    LONDON, UK / ACCESSWIRE / May 24, 2018 / Active-Investors has a free review on Johnson & Johnson (NYSE: JNJ) following the Company's announcement that it will begin trading ex-dividend on May 25, 2018. Active-Investors has initiated due-diligence on this dividend stock. If your portfolio includes dividend stocks, you have come to the right place for timely information.

  • J&J hit with $21.7 million verdict in another talc asbestos cancer case
    Reuters2 days ago

    J&J hit with $21.7 million verdict in another talc asbestos cancer case

    Johnson & Johnson (JNJ.N) and its talc suppliers on Wednesday were hit with a $21.7 million jury verdict in a lawsuit by a woman who said she developed cancer after being exposed to asbestos in the company's Baby Powder. The verdict by a Los Angeles jury came down in the case of 68-year-old Joanne Anderson, who was diagnosed with mesothelioma, a form of cancer closely linked to asbestos exposure, and marked the second trial loss for J&J over similar allegations. Of the $21.7 million the jury awarded in compensatory damages, J&J was assigned 67 percent, with the rest distributed among other defendants.

  • Reuters2 days ago

    J&J hit with $21.7 million verdict in another talc asbestos cancer case

    Johnson & Johnson (JNJ.N) and its talc suppliers on Wednesday were hit with a $21.7 million (£16.2 million) jury verdict in a lawsuit by a woman who said she developed cancer after being exposed to asbestos in the company's Baby Powder. The verdict by a Los Angeles jury came down in the case of 68-year-old Joanne Anderson, who was diagnosed with mesothelioma, a form of cancer closely linked to asbestos exposure, and marked the second trial loss for J&J over similar allegations. Of the $21.7 million the jury awarded in compensatory damages, J&J was assigned 67 percent, with the rest distributed among other defendants.

  • J&J Loses Second Talc-Asbestos Trial and Damages May Grow
    Bloomberg2 days ago

    J&J Loses Second Talc-Asbestos Trial and Damages May Grow

    Johnson & Johnson lost a second trial linking baby powder use to deadly asbestos cancer and jurors must next decide whether to punish the company on top of their award of $21.7 million in damages. Jurors in state court in California concluded Wednesday J&J was liable for Joanne Anderson’s mesothelioma and awarded the 68-year-old compensatory damages. It’s the second jury in less than two months to conclude J&J sold its iconic baby powder knowing it contained at least trace amounts of asbestos and posed a cancer risk to users.

  • Why Geron Corporation Stock Is Heating Up
    Motley Fool2 days ago

    Why Geron Corporation Stock Is Heating Up

    Geron's stock is blasting higher this week, but the exact reason isn't clear.

  • Eli Lilly Gets FDA Approval for Taltz in Genital Psoriasis
    Zacks2 days ago

    Eli Lilly Gets FDA Approval for Taltz in Genital Psoriasis

    Eli Lilly (LLY) gets FDA approval for label expansion of its psoriasis injection Taltz to include data for psoriasis involving the genital area.